<DOC>
	<DOCNO>NCT00314743</DOCNO>
	<brief_summary>The purpose study determine efficacy aprepitant prevent acute delay chemotherapy induced nausea vomit administer combination intravenous oral ondansetron intravenous oral dexamethasone autologous transplant setting .</brief_summary>
	<brief_title>Efficacy &amp; Safety Oral Neurokinin-1 Antagonist , Aprepitant , Combo With Ondansetron &amp; Dexamethasone Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Neurokinin A</mesh_term>
	<mesh_term>Substance P</mesh_term>
	<criteria>Male female patient 18 year age old Patients deem eligible undergo autologous bone marrow peripheral stem cell transplant therapy per usual transplant inclusion exclusion criterion Patients NonHodgkins Lymphoma , Hodgkins Lymphoma Multiple Myeloma Amyloidosis Written inform consent Nausea baseline Chronic use antiemetic agent ( ) Gastrointestinal obstruction active peptic ulcer Radiation therapy pelvis abdomen within 1 week study day 1 Allogeneic stem cell transplant recipient Aspartate transaminase ( AST ) &gt; 3x upper limit normal ( ULN ) Alanine transaminase ( ALT ) &gt; 3x ULN Bilirubin &gt; 3x ULN Alkaline phosphatase &gt; 3x ULN Creatinine &gt; 2 Documented hypersensitivity component study regimen Pregnant lactate woman Participating clinical trial involve investigational agent ( ) Patients take follow medication time study day 1 : warfarin , oral contraceptive ( except administration stop menses ) , tolbutamide , phenytoin , midazolam , ketoconazole , rifampin , paroxetine , and/or diltiazem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Patients Non-Hodgkins Lymphoma Multiple Myeloma</keyword>
</DOC>